Gaining patent protection for drugs is an essential part of
the pharma and biotech sector. Companies seek strong patent
protection so as to prevent the entry of generic competition for
their drugs. Innovator companies often spend 10-15 years to
develop a drug and bring it to market. With a lot of R&D
dollars invested in the development of these drugs, innovator
companies look to gain exclusivity so that they can recover their
investment in product development.
ACTAVIS PLC (ACT): Free Stock Analysis Report
CADENCE PHARMA (CADX): Free Stock Analysis
IMPAX LABORATRS (IPXL): Free Stock Analysis
MALLINCKRODT PL (MNK): Free Stock Analysis
To read this article on Zacks.com click here.
Earlier this week
) said that the United States Patent and Trademark Office granted
a patent (U.S. Patent Number 8,658,631) to Xartemis XR containing
composition claims with regard to its design, formulation,
pharmacokinetic and release characteristics.
Xartemis XR (oxycodone HCI and acetaminophen), an
extended-release oral formulation, is currently under FDA review
for the management of acute pain in a post-surgical model. The
company said that it will launch Xartemis XR in the second
quarter of fiscal 2014, provided the candidate is approved by the
We remind investors Mallinckrodt recently launched another pain
drug, Pennsaid 2%.
Meanwhile, Mallinckrodt is actively focusing on strengthening its
pipeline and promoting new products in the pain market. The
company expects to file for approval for another pain candidate,
MNK-155, in the second half of fiscal 2014.
Earlier this month, Mallinckrodt announced its intention to
Cadence Pharmaceuticals, Inc.
) for about $1.3 billion. With this acquisition, Mallinckrodt is
looking to strengthen its specialty pharma segment. Moreover, the
acquisition will also add another potential growth area for
Mallinckrodt given Cadence Pharma's strong presence in the
Mallinckrodt carries a Zacks Rank #1 (Strong Buy). Other
well-ranked stocks in the healthcare sector include
Impax Laboratories Inc.
). Both carry a Zacks Rank #2 (Buy).